Unicycive Therapeutics (UNCY) Long-Term Debt Issuances (2020 - 2021)
Unicycive Therapeutics (UNCY) reported Long-Term Debt Issuances of $88000.0 for Q2 2021, down 91.29% quarter-over-quarter from $1.0 million in Q1 2021.
Unicycive Therapeutics (UNCY) Long-Term Debt Issuances (2020 - 2021) Analysis & Trends
Unicycive Therapeutics has reported Long-Term Debt Issuances for 2 years, with the latest figure at $88000.0 in Q2 2021.
- For the quarter ending Q2 2021, Long-Term Debt Issuances changed N/A year-over-year to $88000.0; the trailing twelve-month figure through Dec 2021 stood at $1.1 million (changed N/A YoY), and the FY2021 full-year result was $1.1 million, down 14.88% from the prior year.
- Long-Term Debt Issuances for Q2 2021 stood at $88000.0, down from $1.0 million in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $1.0 million in Q1 2021, with the low at $88000.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 2.73 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Unicycive Therapeutics | 174.05 Mn | 119.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 88,000.00 |
| Jun 30, 2021 | 88,000.00 |
| Mar 31, 2021 | 1.01 Mn |
| Mar 31, 2021 | 1.01 Mn |
| Dec 31, 2020 | 390,000.00 |
| Dec 31, 2020 | 390,000.00 |